In latent tuberculosis infection (LTBI) viable Mycobacterium tuberculosis (MTB) bacilli are present in an individual but symptoms and signs of active disease are lacking, and the bacilli are relatively inactive metabolically. In favorable circumstances, some of these inactive bacilli resume greater metabolic activity and replication, leading to the development of active tuberculosis (TB) disease. Treatment of LTBI (TLTBI) is designed to prevent (soon, or in the distant future) this progression from asymptomatic infection to symptomatic, potentially lethal active disease. Several recent excellent reviews have summarized information on TLTBI (also called TB preventive therapy), and these are recommended to the interested reader.
Definition and Scope
In latent tuberculosis infection (LTBI) viable Mycobacterium tuberculosis (MTB) bacilli are present in an individual but symptoms and signs of active disease are lacking, and the bacilli are relatively inactive metabolically. In favorable circumstances, some of these inactive bacilli resume greater metabolic activity and replication, leading to the development of active tuberculosis (TB) disease. Treatment of LTBI (TLTBI) is designed to prevent (soon, or in the distant future) this progression from asymptomatic infection to symptomatic, potentially lethal active disease. Several recent excellent reviews have summarized information on TLTBI (also called TB preventive therapy), and these are recommended to the interested reader. [1] [2] [3] This narrative review is part of a new volume summarizing knowledge on diagnosis and treatment of TB. It draws upon those recent systematic and narrative reviews of LTBI but seeks particularly to include recently published or presented data that are not included in those prior reviews. This review describes the main studies underpinning Centers for Disease Control and Prevention (CDC) recommendations on use of the new 3-month isoniazidrifapentine regimen and points to evolving data that may support future modification of those recommendations.
understanding of dormancy, which is a nonreplicating state of reduced metabolic activity, including transcription and translation. Much has been learned about the biological and environmental factors that govern the shifts between the conditions of active metabolism and replication to those of dormancy. It is now recognized that MTB is capable of "an extensive repertoire of metabolic realignments to enter a defined nonreplicating state." 5 Wayne and Hayes are credited with first demonstrating an in vitro model of MTB dormancy, using gradual depletion of oxygen, and demonstrating a shift in metabolic enzymes, cessation of DNA replication, and reduction but not cessation of RNA synthesis. 6 Since then, multiple other stressful conditions have been shown to favor a shift to latency, including nutritional depletion (amino acids, iron), low pH, exposure to nitric oxide or active oxygen intermediates, and extremes of temperature. 7 The classic studies of McDermott and colleagues established the existence of the state of persistence.
8
Persisting bacilli within a host are viable but nonculturable and are resistant to the action of antibiotics but lacking genotypic resistance; they can be rendered culturable through various interventions, including immunosuppression 9 or the addition of stimulating agents such as the recently described resuscitation promotion factors. 10 It has become clearer that the concept of latency has been oversimplified, and that a useful understanding of the bacillary states variously referred to as latency, dormancy, or persistence will require deeper understanding of microbial physiology and genetics, and the pathological 11 and immunologic 12 responses to infection with MTB.
5

Diagnosis
A separate contribution to this volume discusses diagnosis of LTBI, describing both recent advances and continuing challenges in the diagnosis of a condition for which no true gold standard test exists.
Epidemiology
LTBI remains one of the most prevalent infectious conditions affecting humankind. It is estimated that roughly one third of the global population is infected. 13 In the United States, the National Health and Nutrition Evaluation Survey assessed LTBI prevalence among the civilian, noninstitutionalized, and nonhomeless population in 1999 to 2000 using the tuberculin skin test (TST) and defining LTBI as a positive TST reaction of 10 mm or more. An estimated 11,213,000 (4.2%) individuals had LTBI. Among 25-to 74-year-olds, estimated prevalence had fallen from 14.3% in 1971-72 to 5.7% in 1999-2000.
Higher prevalence was noted in the foreign born (18.7%) compared with the US born (1.8%), and among non-Hispanic blacks/African Americans (7.0%), Mexican Americans (9.4%), and individuals living in poverty (6.1%). A total of 63% of LTBI was among the foreign born. 14 Interestingly, the 60% decline in LTBI since 1971-72 among persons aged 25 to 74 was roughly parallel to the 63% decline in reported TB cases since 1972, and the proportion of persons with LTBI who were foreign born represented roughly 60% of the estimated total.
A repeat survey was performed in 2011-12 and will be reported soon.
Clinical Relevance
A variety of clinical factors have been recognized as associated with risk of progression from LTBI to active disease (►Table 1).
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It is remarkable that most tables such as this do not mention the most widely appreciated risk factor for development of TB, namely current or recent treatment of active TB. The notable studies of the British Medical Research Council documented combined failure/relapse rates during or after rifampin-based short-course chemotherapy of 2 to 5%. 16 Patients in these circumstances (during or after the continuation phase of therapy for active disease) are presumed to have only a few dormant (persisting) bacilli. Some of these patients (those with cavitary TB who respond slowly to therapy) have risks of relapse after therapy of 20 to 25%.
17
These rates are clearly higher than those seen in persons identified in contact investigations in the United States, and thus such persons may merit consideration for additional therapy to eliminate LTBI (see Special Circumstances: HIV later in this article)
Animal Models
The most informative animal model of TB has been the murine model. Early murine studies focused on treatment of active disease, but Grosset and Mitchison began in the 1990s to examine models of latent infection as well.
18-20
They used different mouse models that sometimes gave conflicting results.. 18, 20, 21 These studies provided support for the 2-month rifampin and pyrazinamide regimen, as well as for regimens based on weekly rifapentine. More recently, Grosset's group reported on murine studies which suggest that isoniazid (INH) and rifapentine may be effective as TLTBI using very short periods of daily therapy, and bedaquiline may be effective in the treatment of LTBI due to multidrug resistant (MDR) strains.
22,23
Treatment
The use of anti-TB drugs to prevent development of TB disease among persons known or suspected to be infected with MTB began with Edith Lincoln's efforts to prevent progression of primary TB to meningitis among recently exposed children seen at Bellevue Hospital. 4 In 1959 at the Arden House hepatotoxicity associated with INH therapy (see later discussion). Inclusion of LTBI treatment in the context of contact investigation elevated preventive therapy in the national strategy to control tuberculosis. The concern about INH toxicity also spurred interest in alternative regimens, and over the past 20 years investigators have assessed several different rifamycin-based regimens, generally of shorter duration, both with and without companion drugs. Increasing recognition of MDR-TB (i.e., TB resistant to both INH and rifampin) and the difficulties encountered in its treatment have stimulated interest in the use of preventive therapy among contacts of MDR-TB.
Efficacy of Drugs and Regimens
Isoniazid Alone
INH was the first anti-TB agent to be employed successfully for preventive therapy, and by far more is known about its performance as a prophylactic therapy than is known for any other anti-TB drug. Abnormal chest X-ray-granuloma 2
Low risk (testing and treatment for LTBI recommended if age < 35 years)
Infected person, no known risk factor, normal chest X-ray ("low-risk reactor") 1
Very low risk (treatment of LTBI not usually recommended)
Person with positive two-step ("boosting"), no other known risk factor, and normal chest X-ray 0. outcome based solely on X-ray changes; efficacy was only 4%, but protection was 42% among those who were TST positive. 35 There was not a statistically significant difference among the three active arms; the placebo arm had significantly more TB cases by 5 years of follow-up. The rifampin-only arm performed more favorably than any other. It also had fewer hepatic reactions reported. INH-resistant TB occurred in all arms, most commonly in the 6H arm; rifampin resistance appeared only in the placebo arm. In the discussion of this trial, the authors commented on the potential utility of longacting rifamycins such as rifapentine.
In recent years, attention has focused on three types of rifamycin-based short-course regimens for treatment of LTBI. These are (1) 3 to 4 months of rifampin, alone or in combination with INH; (2) 2 to 3 months of rifampin and pyrazinamide; and (3) 3 or fewer months of INH and rifapentine:
(1) Interest in rifampin-only regimens has increased since the option of 4 months of rifampin (4R) was recommended (as an acceptable alternative for INH-resistant LTBI) in the 2000 revision of the US guidelines, largely based on the MRC trial in silicotics (which used only 3 months of R, not 4; ►Table 2).
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On the strength of this recommendation, several programmatic assessments of the 4R regimen have been published. [45] [46] [47] [48] Menzies and colleagues in Montreal have been most engaged in the assessment of 4R as an alternative to 9H. They have published a pilot study, 49 a study of adverse events, 50 and two studies of costs 51, 52 and are currently guiding a large (planned sample size of 5,720) multinational trial comparing 4R with 9H in the treatment of LTBI. 53 The trial's results will be available in 2016 at the earliest. HIV-infected persons. In general these trials showed no significant differences between the shorter-duration HR combination arms and the longer INH-only arms, which were similarly effective, had similar rates of serious adverse events, and had similar rates of completion of therapy.
(2) The combination of rifampin and pyrazinamide as therapy for LTBI was considered as early as the 1980s. 65 Grosset and colleagues reasoned that since the therapy of active TB had been shortened from 18 to 6 months through the addition to INH of rifampin and pyrazinamide, the addition of either or both drugs might shorten the necessary duration of INH preventive therapy to something well below the 6 months shown to be effective in the IUAT prophylaxis trial. 38 In addition, they pointed out that studies in Hong Kong had demonstrated that smear-negative and culture-negative TB disease could be effectively treated with 4, 3, or even 2 months of a four-drug regimen (►Table 3). 66 If culturepositive relapse were considered in the 1976 study to represent progression of LTBI, then the daily four-drug 3-month regimen was 88% effective after 5 years of follow-up. Grosset's studies tested the efficacy of rifampin alone or in combination with INH and/or pyrazinamide in a murine model of LTBI.
65 Surprisingly the most effective regimens were 2 months of rifampin-pyrazinamide or 3 months of rifampin alone. This work created great interest in the potential of a 2-month LTBI regimen of rifampin-pyrazinamide (2RZ). Further, most experts consulted by the World Health Organization (WHO) were at the time unwilling to recommend a regimen using rifampin alone, for fear of engendering rifamycin resistance (pers. comm., Dr. R. O'Brien 
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(3) Two decades after the authors of the Hong Kong study of silicotics had speculated about an LTBI treatment regimen using rifapentine, three different trials reported on the performance of a regimen of once-weekly INH and rifapentine (►Table 4). [77] [78] [79] Murine models had supported the use of such a regimen. [80] [81] [82] [83] The three human trials were performed in Rio de Janeiro, in Johannesburg, and in the United States, Canada, Brazil, and Spain. The first trial randomized participants either to 2 months daily rifampin and pyrazinamide or to 3 months once-weekly INH 900 mg plus rifapentine 900 mg. 77 This trial was halted early due to an elevated rate of hepatotoxicity in the 2RZ arm. Most of the participants were TST-positive, HIV-negative household contacts to active cases. Adherence was high, and both regimens appeared effective; the 2RZ regimen had fewer cases (one vs three) but the rates were low and not significantly different (0.5% vs 1.5%). Studies in Boston and in Rio de Janeiro had indicated that 8 to 9% of infected close or household contacts develop active disease if untreated. 42, 84 The second study randomized 78 Adherence was high for all four regimens. There were no significant differences among the four regimens in rates of active TB (range 1.4 to 2.0 per 100 person-years) or death (range 1.3 to 2.1 per 100 person-years). The continuous INH regimen was nonsignificantly more favorable with regard to these two outcomes but sustained significantly more adverse events during the longer course of therapy. Also of concern was the occurrence of one rifampin-monoresistant TB case among persons given the 3HP regimen, suggesting the possibility that incipient TB disease remains difficult to exclude with certainty during screening of patients in this high-risk setting. 85 The third trial, TBTC (TB Trials Consortium) Study 26, was the largest comparative US trial of preventive therapy in the past 40 years, enrolling 8,053 participants. 79 It randomized subjects to either 9 months of daily self-administered INH 300 mg (9H) or 3 months of onceweekly INH 900 mg and rifapentine 900 mg (3HP). Included were TST-positive close contacts to active TB ($ 70% of persons enrolled), documented recent TST converters ($ 26%), HIV-positive persons with positive TST or recent TB contact (2%), or TST-positive persons with fibrosis on chest X-ray (2%). Completion of therapy was 69% in the 9H arm and 82% in the 3HP arm. Twenty-two cases occurred during the 33 months of therapy and observation; the rates were 0.43% in the 9H arm and 0.19% in the 3HP arm, sufficient to satisfy the criteria of noninferiority specified in the trial's revised analytic plan. The event rates were low in this trial; among 384 subjects who received two doses or less of combination therapy, or less than 30 days of INH only, but who remained in the study, there were four tuberculosis cases, for a cumulative rate of 1.64%. This was, however, comparable to the rates observed in the IUAT (5-year incidence in the placebo arm of 1.43%) 38 and USPHS-Contact studies.
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Of the 22 cases, 20 were confirmed on culture. There were two INH-resistant cases (both in the INH-only group) and one rifampin-resistant case (in the 3HP arm). The latter case occurred in a subject with HIV infection (CD4þ cell count ¼ 271 per mm 3 at enrollment) and INH-susceptible M. bovis infection (also considered to be culture-confirmed TB) who had treatment interruptions and completed therapy late. This was one of the very few recent studies that enrolled children. Because the numbers of persons with HIV and the numbers of children were low, enrollment of these two groups was extended; ultimately 393 HIV-positive persons and 539 children under 12 years of age were enrolled. Many of these HIV-positive persons are still in follow-up, with final results expected in 2013. Preliminary assessment indicated that, among HIV-positive persons not receiving ART, 3HP was better tolerated and had higher treatment completion rates than 9H for treatment of latent M. tuberculosis infection.
86
Similar findings concerning tolerability of 3HP applied to children aged 2 to 17 years; moreover, efficacy data in Table 4 Trials of once-weekly isoniazid 900 mg þ rifapentine 900 mg in LTBI children were presented when 96% of follow-up had been completed, and noninferiority of 3HP was affirmed in this important age group.
87
Serious adverse events occurred in 1.6% of 3HP patients and 2.9% of 9H patients. Investigator-assessed drug-related hepatotoxicity occurred in 0.4% and 2.7%, respectively. Possible drug-related hypersensitivity occurred in 3.8% and 0.5%. The adverse event experience in this open-label trial was complex, and detailed analysis is still under way. Six of the suspected hypersensitivity occurrences involved hypotensive episodes (systolic BP < 90). Some of these adverse event episodes likely represent rifamycin hypersensitivity, or "flulike syndrome." 88, 89 Hypersensitivity and flulike syndrome have been reported with other long-acting rifamycins.
90,91
The experiences with hepatotoxicity due to INH and to 2RZ noted earlier have led to increased caution surrounding the introduction of new LTBI regimens; concern also persists regarding the potential for once-weekly rifapentine regimens to foster the development of rifamycin resistance in persons with active TB and advanced HIV.
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Nevertheless, compared with 9 months of INH, the potential logistical advantage of an effective and well-tolerated 3-month regimen for LTBI is enormous. Simultaneous with publication of the Study 26 findings, CDC published guidelines for use of the new 3HP regimen in the United States.
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Those guidelines recommended use of the 3HP regimen as an equal alternative to the 9-month INH regimen for many persons ! 12 years of age; future publication of the pediatric data cited earlier may lead to modification of the recommended lower age limit. Due to lack of data, the 3HP regimen was not recommended for use in persons with HIV on ART; if permissive data on interaction with ART become available, then use of the 3HP regimen in HIV-infected persons receiving ART might be reconsidered. CDC's TB Trials Consortium began in 2012 a trial assessing self-administration of this 12-dose regimen; if findings from this trial support selfadministration, then the current recommendation that the regimen be given under direct observation may be modified. CDC's TB Epidemiologic Studies Consortium has begun a large (expected enrollment > 40,000) observational study of LTBI at 20 US sites. CDC has initiated an additional multisite phase 4 implementation trial of 3HP. Finally, the existing CDC system for surveillance of severe adverse reactions to any LTBI regimen 93 includes a focus on the new 3HP regimen.
Interest in even shorter HP regimen is strong. Based on promising data from murine studies, 22, 23 the Adult AIDS Clinical Trials Group network has begun a study of an ultrashort daily regimen of INH 300 mg and rifapentine (300 to 600 mg, based on weight) given for 4 weeks to HIV-infected persons with positive TST or living in a high-burden country. 94 If successful, it is likely that such a regimen would be studied in HIV-negative persons as well.
Adverse Effects
Isoniazid
Adverse effects from anti-TB medications have been described throughout the history of TB pharmacotherapy, but 
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Not surprisingly, these reports generated continuing concerns about the frequency of INH-associated hepatotoxicity. In the IUAT study, hepatitis attributable to INH therapy occurred in $ 2% of persons in the first 12 weeks, and $ 1% more in each subsequent 3-month period (cumulative rate $ 5%). 38 A series of cost-benefit studies has assessed the relative value of INH preventive therapy in the face of these potential risks. 
Rifamycins
Rifamycins have proven to be relatively safe drugs, with over 40 years' experience in their use. The best known of their side effects is the induction of cytochrome P450 enzymes, particularly CYP3A4, with a resultant increase in the metabolism of a wide variety of drugs (including anticoagulants, oral contraceptives, methadone, and anti-HIV protease inhibitors).
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Other recognized toxicities include hepatotoxicity (significantly less than with INH), and a variety of severe reactions thought to be immunologic in origin. These include hematologic reactions such as thrombocytopenia and hemolytic anemia, renal reactions such as acute tubular necrosis and interstitial nephritis, and flulike syndrome. 89 These immunologic reactions are believed to occur more often when therapy is intermittent and possibly with higher doses, 88, 117 and may be due to antibody-mediated reactions.
118,119
Cost Considerations
Much of the attractiveness of preventive interventions lies in their potential to reduce costs. Cost-effectiveness analyses have had an important impact upon the uptake of LTBI therapy. The early appeal of such measures derived from the expectation that TLTBI would avert deaths in both children and adults. Enthusiasm was tempered by the early experiences with INH-related hepatotoxicity. Although the IUAT study found greatest protection with 12 months of INH, a subsequent cost-effectiveness study using rates from this trial found that 6 months of therapy provided the optimal cost benefit, compared with 3 or 12 months. 39 
136-141
The review by Akolo et al reported that individuals with a positive TST had a significant 62% reduction in incident TB, whereas those with a negative TST did not have a significant benefit (RR 0.89, 95% CI 0.64 to 1.24). 135 This is consistent with a review of 11 studies (both HIV negative and HIV positive) by Watkins et al, who reported a positive association between TST reactivity and incidence of TB.
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Interestingly, this effect of TST-positivity was also quite strong in the recently reported Botswana randomized trial by Samandari et al comparing 6 and 36 months ("continuous") of INH in HIV-positive persons. 143 The authors reported a 43% Attention has also been directed toward the impact of ART upon TB incidence in settings of high HIV and TB prevalence. The effect of IPT in the Botswana study was independent of and additive to the TB-preventive effect of ART. By study completion, 946 (47%) of 1995 participants had initiated ART. Regardless of TST status, TB incidence was reduced by $ 50% in those receiving 360 days of ART compared with participants receiving no ART (adjusted HR 0.50, 95% CI 0.26 to 0.97). In those on continuous INH who also received ART, the reduction was 96% (HR 0.04, 95% CI 0.005 to 0.35). A recent systematic review reports an overall hazard ratio of only 0.35 in persons with HIV and on ART while living in developing countries. 145 Another such review found that, even throughout ART and despite achievement of high CD4 cell counts, TB incidence remains over fourfold greater than in persons without HIV. 146 A recent trial of IPT given for 12 months to persons with HIV who were on or beginning ART in Cape Town, South Africa, reported a 37% reduction in hazard of TB; most of the reduction appeared to occur during the active INH treatment period and diminished during later follow-up, and there was no significant mortality benefit.
147
Further, TB preventive therapy does not appear to prevent death among persons with HIV who are TST-negative, [137] [138] [139] 141, 142 in contrast to earlier speculation that many such persons might be TB-infected but anergic due to advanced HIV disease. Another area of debate is that of secondary prophylaxis in persons already treated for active TB. At least two trials have demonstrated benefit from such an approach. 148, 149 These two trials both demonstrated substantial benefit when HIVinfected persons completing treatment for active TB were given an additional 6 months of INH or INH plus rifampin therapy (however, both studies employed a relatively weaker twice-weekly continuation phase, and a regimen of only 6 months overall).
The CREATE Studies
Interest in strategies to prevent TB among persons with HIV in high-prevalence settings led the Bill and Melinda Gates Foundation to fund CREATE (Consortium to Respond Effectively to the AIDS/TB Epidemic). 150 CREATE included three large-scale, cluster-randomized studies of strategies to diminish death and disease from TB in communities with high rates of HIV/AIDS; each included some element of LTBI treatment with INH:
1. In the Thibela TB study in South Africa, all 80,000 employees in 15 randomized mine shafts received either standard care or enhanced TB mobilization and screening and access to 9-month IPT. This was the largest trial of IPT ever undertaken. The incidence rate ratio (IRR), adjusted for gender, age, and place of work, was 1.0 (95% CI 0.77 to 1.31); prevalence was also unaffected (PRR 0.95, 95% CI 0.83 to 1.10). Failure to obtain a population effect was attributed to a high rate of nonadherence to IPT. At the individual level, among persons who started IPT, the IRR in months 0 to 8 was significantly lower (aIRR [adjusted incidence rate ratio] ¼ 0.37, 95% CI 0.19 to 0.72), corresponding to a 63% decrease in TB incidence compared with controls. However, this effect was not durable, with IRRs of 1.0 and 0.79 in the periods 9 to 18 months and > 18 months following the IPT treatment period.
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2. In the ZAMSTAR study, in Zambia and South Africa, 24 communities (total population $ 962,000) were randomized to each of two separate interventions: (a) enhanced case finding at clinic, school, and community levels; and (b) a household intervention using the TB patient as the gateway into the household, to offer group education, home-based screening for TB and HIV, and increased access to IPT and ART through counseling and referral. The ZAMSTAR outcomes were survey-measured prevalence of TB and rate of TB transmission measured as change in TST-positivity among school-aged children (►Table 5). 3. The third CREATE study, called THRio, was a phased implementation study (using a stepped-wedge design) of tuberculin skin testing and INH preventive therapy (IPT) for TST-positive (! 5 mm) persons in 29 HIV clinics in Rio de Janeiro, Brazil. 153 The primary end points were 
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incidence of TB and TB or death at the clinic level before and after the intervention. Intent-to-treat (ITT) analysis included all eligible individuals enrolled; modified ITT (mITT) analysis considered participants who remained in clinic contact at least annually ("stayers"). Crude rates of TB and TB/death in the control period were 1.31 and 3.67/100 person-years (PYs) versus 1.10 and 3.01/100 PYs in the intervention period. Adjusted and unadjusted ITT and mITT Cox regression results are shown in ►Table 6.
Taken together, findings from the three CREATE trials suggest that IPT can have a substantial impact on TB in communities with high rates of HIV, but that impact can be vitiated by lack of adherence and is likely enhanced by targeting of IPT to those with positive TST reactions. Analysis of these remarkable trials is still in an early stage, and discussion of their results and implications is likely to continue for some years.
Drug Resistance
Two issues have arisen with regard to drug resistance and TLTBI:
1. The first concerns the potential to create resistance through the use of single-drug therapy. Ferebee concludes in a 1970 review that INH resistance does not occur more frequently in cases developing after INH prophylaxis than in cases developing after receipt of placebo, but the evidence cited is highly incomplete. 32 Balcells et al reported that treatment of LTBI with INH was associated with a nonsignificant 1.45-fold higher risk of INH-resistant TB compared with the background incidence in the same population. 154 They assessed trials among HIV-negative and HIV-positive populations separately. It is safe to say that there are only limited reports of INH resistance in cases occurring after prophylaxis, consistent with the current view that LTBI is a paucibacillary state in which the bacillary populations are low enough to make spontaneous resistance mutations unlikely. However, it is also clear that failure to eliminate subclinical disease, which is not uncommon in HIV-positive populations in high-burden settings, could expose persons receiving INH prophylaxis to a significant risk of acquired resistance to INH. The same problem might exist with rifamycin-based LTBI treatment regimens. Acquired resistance to rifampin has not been reported as a frequent problem with rifampinbased regimens, but the existing database is relatively modest. Of the three trials that have assessed once-weekly rifapentine-based regimens, two have reported acquired rifamycin resistance. TBTC Study 26 noted that one of seven cases in the once-weekly arm (occurring among 3,986 persons in that arm, of whom 105 were HIVinfected) occurred in an HIV-positive patient with rifampin-resistant M. bovis. 79 Resistance was not reported among the three cases (out of 206 persons) that were diagnosed in those receiving once-weekly therapy in the Brazil trial; only 1 of the 206 was HIV-positive. 77 In the Soweto trial in HIV-infected persons, one case of MDR-TB was noted in the once-weekly INH-rifapentine arm, and one in the continuous INH arm; in addition, one case of rifampin monoresistant TB was diagnosed among 21 culture-confirmed TB cases in the rifapentine arm (n ¼ 328). 78 Thus, in three prophylaxis trials there have been two rifampin-monoresistant TB cases among 434 HIV-infected persons receiving prophylaxis. None of these trials admitted persons on ART; it would be helpful if acceptable ART could be defined for the once-weekly regimen. 2. The second involves the use of preventive treatment for persons exposed to drug-resistant TB. In the case of INH resistance, the use of rifampin-based preventive therapy has been noted earlier. For prophylaxis of MDR-LTBI (LTBI due to multiple-drug-resistant TB), a variety of regimens have been tried (notably regimens of a newer fluoroquinolone, with or without a companion drug such as ethambutol, pyrazinamide, or ethionamide, or combinations of two of the latter drugs). Only relatively small case series are available to assess such regimens. 155 A recent Cochrane review found no trials of MDR prophylaxis suitable for a systematic review. 155 The same authors reviewed two case series and concluded that INH was not effective and that individualized therapy could be useful. 
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Future Directions
There is strong evidence that use of treatment for LTBI can prevent future TB cases in high-risk settings such as recent close contact to an active case (see ►Table 7 163-175 for a listing of LTBI treatment trials). Such treatment clearly prevents cases of TB, prevents deaths from TB, and thus provides benefit to some of the individuals treated. What is less clear is how this intervention can be applied in cost-effective ways. Recent investigations, including both clinical trials and epidemiological studies, suggest that some 50 to 70% of cases due to recent transmission have already occurred by the time current contact investigations identify and evaluate the individuals at risk. 176 This means that the "number needed to treat" is not 10 to 20 (if risk were 5 to 10%), but rather 40 to 67, which may have significant influence on the long-term impact of this strategy. Models that have favored use of LTBI treatment need to be reevaluated in light of this new information on efficiency.
177
The discussion on use of TLTBI is also hindered by confusion between treatment of LTBI in low-prevalence settings and use of IPT in settings of high TB and HIV prevalence. In the latter setting, much of the benefit of IPT derives from (1) prevention of TB-related death, which occurs at higher rates in these settings, and (2) prevention of reinfection (which may be an important gain where TB transmission is intense, and a nonexistent gain in settings where it is not). Few studies to date have been able to make this distinction, and many trials of TB treatment are too small to distinguish reliably among these various outcomes. Moreover, there remains controversy about the role of testing for LTBI in high-prevalence settings. WHO policy makers recommend use of IPT for all HIV-infected persons in these settings, but most studies show little or no benefit accruing to those who are TSTnegative. Other areas of uncertainty include the utility of rifabutin in treatment of LTBI, and the role of novel compounds in the prophylaxis of MDR-TB. Ongoing trials of INHrifapentine regimens and of 4R will add to our understanding and increase the effective use of these important preventive therapies.
Disclaimer
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